ClinicalTrials.gg

Program

SHR-4394

A development code. Also written as “SHR4394”.

In Jiangsu HengRui Medicine's pipeline, PSMA ADC. Its studies are mostly in Prostatic Neoplasms, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Feb 6, 20262 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine22 open or runningphase 2since Feb 6, 2026Jan 14, 2025Mar 2027phase 1 · NCT06783829
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-4394, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 14, 2025First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT06783829 · 240 planned · China
  2. Feb 6, 2026Phase 2 study in Prostatic NeoplasmsPhase 2 reachedNCT07407283 · 100 planned · China

Ahead

  1. Mar 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT06783829
  2. Nov 2027Primary completion: phase 2 study in Prostatic NeoplasmsNCT07407283

TargetBeta

“PSMA ADC”the company's pipeline, read by Claude · source

Other programs on FOLH1

ProgramCompanyFurthest phaseStudies
flotufolastat F 18ruleBraccophase 47
piflufolastatruleLantheusphase 45
abefolastat tesaroxetan CU-64ruleclarity-pharmaceuticals-ltdphase 35
gallium 68 PSMA-11ruleNovartisphase 34
Lutetium Lu 177 Ludotadipeprulefuturechemphase 33
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 32
Lutetium Lu 177 NYM032ruleNorroy Biosciencephase 32
actinium AC-225 vipivotide tetraxetanNovartisphase 32
HRS-4357Jiangsu HengRui Medicinephase 32
zadavotide guraxetanAstraZenecaphase 24
AB-001rulefrontier-biotechnologies-incphase 23
olsutamigruleRegeneron Pharmaceuticalsphase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07407283Prostatic Neoplasms · China2RecruitingNov 2027100
NCT06783829Prostatic Neoplasms · China1RecruitingMar 2027240

How it is read

Names in the registry

  • “SHR-4394”, 1 entry
  • “SHR4394”, 1 entry

Codes read as this program: SHR4394.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.